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Diabetes-prone (DP)' BB rats develop spontaneous hyperglycemia and ketoac-
idosis that is fatal unless treated with insulin, and many lines ofevidence indicate
that the disorder has an autoimmune pathogenesis (1). Lymphocytic infiltration
of the islets of Langerhans (insulitis), selective destruction of insulin-secreting #
cells (2-5), and circulating islet autoantibodies (6-9) are observed. The disease
is associated with the RTl° allele of the rat MHC (10) and is prevented by
immunosuppression (11, 12), thymectomy (13, 14), bone marrow allografts (15,
16), and lymphocyte transfusions (17-20). Con A-activated spleen cells from
acutely diabetic BB rats adoptively transfer diabetes to naive recipients (21-23).
DP-BB rats also have many abnormalities of cell-mediated immunity, including
severe T cell lymphopenia (24-27).
Histocompatible diabetes-resistant (DR) BB rats have also been developed (28,
29). <3% ofthem develop spontaneous diabetes, compared with 40-70% of DP
rats, and they appear to have an intact immune system with normal numbers of
peripheral lymphocytes. The frequency of diabetes in DR-BB rats can be sub-
stantially increased by treating them with low-dose irradiation (30) or cyclophos-
phamide (23).
These observations on the DR-BB rat are of particular interest in light of the
finding (31) that RT6+ T cells are absent in the DP-BB rat but present in the
DR in numbers similar to those found in normal Wistar Furth rats. The RT6
alloantigenic system (formerly termed ART2, Pta, AgF, and RTLy-2) consists of
two allelic genotypes, RT6a and RT6b (32, 33). The surface antigen expressed
by the RT6a genotype is designated RT6.1; that expressed by RT6bis designated
RT6.2. RT6 is a nonglycosylated 21-kD surface membrane molecule (34) ex-
pressed on 60% of peripheral rat T cells but absent from thymocytes and bone
marrow cells (35, 36). ^-50% of helper/inducer (W3/25+) and 70% of cyto-
toxic/suppressor (OX8+) peripheral Tcells express RT6 (36). RT6+ lymphocytes
participate in graft versus host responses (37), proliferate in response to Con A
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and to allogeneic stimulation in MLRs (38), and secrete IL-2 (Lubaroff, D. M.,
personal communication). Cell fractionation studies suggest that RT6+/OX8+ T
cells may be suppressors of in vitro MLRs (38) and antigen-specific proliferative
responses (Mojcik, C. J., D . L . Greiner, 1. Goldschneider, and E. S. Medlock,
manuscript in preparation.
Previous studies have suggested that RT6+ T cells may play a role in deter-
mining susceptibility to diabetes in DP-BB rats. Diabetes in RT6-deficient DP
rats can be prevented by transfusions of DR-BB (17, 19) or Wistar Furth (18,
20) spleen and lymph node cells, and protection is associated with long-term
persistence of donor-origin RT6+ T cells in the transfused recipients.
To investigate further the role ofRT6+ T cells in BB rat diabetes, we selectively
depleted DR rats of RT6.1+ T cells by in vivo administration of an anti-RT6.1
lymphocytotoxic mAb. Our results show that depletion of RT6+ T cells in young
DR rats induces insulitis and diabetes and that RT6-depleted DR spleen cells
induce rather than prevent diabetes.
Materials and Methods
Animals.
￿
DP and DR rats were obtained from the University of Massachusetts in
Worcester (BB/W rats). DP-BB/W rats have been inbred for over 20 generations and
have a cumulative incidence of diabetes between 40 and 70%. <0.5% become diabetic
before 60 d of age, and >85% of diabetics appear between 60 and 120 d of age. RT6+ T
cells are not found in DP-BB/W rats at any age (31).
DR-BB/W rats were derived from fifth generation DP forebears and have subsequently
been inbred for resistance to diabetes for over 20 generations. At the time of these
experiments, the cumulative incidence of diabetes in the DR-BB/W rat was <3%, with
most cases occurring before 60 d of age. Insulitis among nondiabetic DR-BB/W rats is
rare. DR-BB/W rat T cells express the RT6.1 phenotype. The MHC haplotype of all BB
rats is RT I".
Lewis (LEW, RT1', RT6') and Wistar Furth (WF, RT1°, RT6') inbred rats were
obtained from the Animal Genetics and Production Branch, National Cancer Institute,
Frederick, MD. All rats were housed under standard laboratory conditions, provided with
water and commercial chow ad libitum, and tested for diabetes twice weekly. In all
experiments, diabetes was diagnosed on the basis of 4+ glycosuria and a plasma glucose
>200 mg/dl.
Antibodies.
￿
Rat-mouse hybridoma cell lines secreting mAb to the RT6.1 (DS4.23) and
RT6.2 (6A5) allelic forms of the RT6 peripheral T cell subset were prepared in our
laboratory as previously described (35). The 6A5 cell line was the gift of Dr. D. M.
Lubaroff, University of Iowa, Iowa City. W3/25 (helper/inducer T cell subset) and OX8
(cytotoxic/suppressor T cell subset) mouse mAbs were obtained from Accurate Chemical
& Scientific Corp., Westbury, NY (39).
In Vivo Administration of mAb.
￿
DS4.23 anti-RT6.1 mAb was prepared for in vivo
injection using hybridomas grown in tissue culture for 72 h in serum-free RPMI 1640
containing I % Nutridoma-SP (Boehringer Mannheim Biochemicals, Indianapolis, IN).
Cell-free tissue culture supernatant was concentrated 100-fold using a filtration system
with a molecular weight cutoff of 50 x 10' (Amicon Corp., Danvers, MA) . The protein
content of concentrates was measured and the volume was adjusted to provide for the
intravenous injection of 0.1-2.5 mg protein/kg body weight in 0.5 ml RPMI. Litters of
male and female DP and DR rats were randomized to receive injections of mAb or
medium. Experimental protocols are detailed below. In all experiments, representative
animals from each injection group were killed for analysis of lymph node cell subsets by
flow cytometry.
Immunofuorescence Analysis.
￿
Spleen and lymph node cell suspensions were prepared
by extrusion of the tissues through a cell sieve followed by trituration with a PasteurGREINER ET AL.
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pipette. Cells were washed with at least two changes of cold RPMI 1640 medium and
viability was determined by exclusion of 0.1 % trypan blue.
Cell suspensions were labeled by incubation with anti-RT6.1 or anti-RT6.2 mAb,
followed by incubation with an F(ab')2 fragment of FITC-conjugated goat anti-rat IgG
antibody (heavy and lightchain-specific; Cappel Laboratories, Malvern, PA) as previously
described (40), or by incubation with anti-RT6 .1 mAb that had been directly conjugated
with FITC (36). Cells labeled with mouse mAb OX8 or W3/25 were developed for
immunofluorescence analysis using an F(ab')2 fragment of a FITC-conjugated goat anti-
mouse IgG (heavy and light chain-specific) antibody that had been passed over a normal
rat serum Sepharose 4B affinity column to remove crossreacting antibodies (31). Controls
routinely included the FITC conjugate aloneor irrelevant rat and mouse mAb substituted
for the primary antibodies. All cell suspensions were fixed before analysis using saline-
buffered 10% formalin .
Cell suspensions prepared for immunofluorescence were analyzed visually using a Zeiss
fluorescence microscope or electronically on a FACS IV (Becton Dickinson & Co.,
Sunnyvale, CA), according to relative low-angle light scatter (1 .5-15°) and relative
fluorescence intensity as previously described (40). Dead cells and red blood cells were
excluded from analysis by electronic gating. At least 5 X 104 nucleated cellswere analyzed
for relative fluorescence intensity.
Mitogenic Response ofLymphocytes to ConA.
￿
The proliferative response ofRT6-depleted
DR-BB/W spleen cells to various doses of Con A (0.125-1 .0 ug/well) was measured by
[3H]thymidine uptake as previously described (41). Measurements at each dose of Con A
were performed in triplicate and averaged.
Preparation ofLymphocytesforAdoptive Transfer ofDiabetes.
￿
Spleen cells were prepared
for adoptive transfer as previously described (21). Briefly, spleen cell suspensions were
prepared aseptically, washed three times with cold RPMI 1640, and then cultured in
RPMI supplemented with 10% FCS, 100 U/ml penicillin, and 5 ug/ml Con A (Miles-
Yeda, Rehovot, Israel) for 72 h at 37°C in the presence of 5% C02. After incubation,
the cells were washed, resuspended in RPMI and tested for viability by exclusion of 0.1
trypan blue. Each recipient rat received 40 X 106 viable cells intravenously via the tail
vein. Adoptive transfer ofBB rat diabetes without Con A activation has not been described
(1). The phenotype of the cell(s) responsible for transfer remains unknown.
Histologic Procedures.
￿
Pancreata obtained at the end of an experiment were fixed in
Bouin's solution and embedded in paraffin. Sections stained with hematoxylin and eosin
were examined for insulitis by a pathologist (Dr. M. C. Appel, University of Massachusetts,
Worcester, MA) who was unaware of the treatment status of the rats.
Statistical Procedures.
￿
Statistical analysis of the frequency of diabetes used the X 2 and
Fisher exact statistics (42). The Bonferroni adjustment for multiple comparisons (42) was
made where appropriate. Only animals surviving either to the end of the experiment or
to the onset of diabetes are included. Insulitis was scored as either present or absent,
without regard to severity.
Experimental Protocols. Experiment 1 quantified the in vivo effect of anti-RT6.1
antibody injections on lymph node cell populations of DR-BB/W, LEW, and WF rats. 30-
d-old DR-BB/W (RT6a) animals were given one intravenous injection of DS4.23 (anti-
RT6 .1) at a dose of 0.1-2.5 mg mAb/kg body weight. 30-d-old WF (RT66) and LEW
(RT6a) rats, and 60-d-old DR-BB/W rats were also tested at a dose of 0.3 mg/kg. Controls
were given injections of RPMI 1640. 24 h after mAb injection, the rats were killed and a
sample of lymph nodes was removed. Aliquots of pooled lymph node cells were labeled
by incubation with anti-RT6 .1, anti-RT6.2, OX8, W3/25, or anti-Ig antibody and devel-
oped for immunofluorescence. The results of this study determined the dosage of anti-
RT6 .1 used in subsequent experiments.
Experiment 2 quantified the frequency of diabetes in 30-d-old DR-BB/W and LEW
rats and in 60-d-old DR-BB/W rats given 0.3 mg/kg anti-RT6.1 antibody intravenously
twice weekly for 4 wk. Control rats received RPMI 1640. All rats were tested for diabetes
from the day of the first injection until 1 wk after the last one, at which time repopulation
of RT6+ T cells could be anticipated. The number ofrats in each group is given in Table464
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TABLE I
Phenotypic Analysis of RatLymph Node CellsAfter In Vivo Administration ofAnti-RT6.1 mAb
Rats were given a single intravenous injection of DS4 .23 anti-RT6.1 mAb (0.3 mg/kg) or RPMI
1640 medium. 24 h after injection, lymph node cells were recovered and the mean percentage of
total lymph node cells bearing each marker was determined by immunofluorescence analysis on the
FACS using at least 50,000 nucleated cells. Results represent the mean of pools of three or four
animals. Values of<1.0% indicate that no cells bearing this marker were detected.
11. During the final week of mAb injections, depletion (>95%) of RT6+ lymph node cells
in a representative sample of treated rats was confirmed by immunofluorescence analysis.
Experiment 3 was designed to determine if cells capable of the adoptive transfer of
diabetes couldinduce the disease in nondiabetic DR-BB/W or LEW rats depleted of RT6+
lymphocytes. Previous studies (23) had shown that intact rats of both strains are resistant
to the induction of diabetes by this method (23). DR-BB/W rats are, however, susceptible
to the adoptive transfer of diabetes by this method if they are first immunosuppressed
(23). Treatment of DR-BB/W rats with mAb was begun at either 30 or 60 d ofage; LEW
rats were treated beginning at 30 d of age. Control rats were given injections of RPMI
1640 on the same schedule. After treatment with mAb for 3 wk (a total of six injections),
DR rats were tested for diabetes and those that had remained nondiabetic were selected
for further study. Both control and experimental animals were given a single intravenous
injection of 40 X 106 Con A-activated spleen cells from acutely diabetic BB/W rats. Twice
weekly injections of mAb or RPMI continued after injection of the Con A-activated cells
until the conclusion of the experiment. Animals were tested for diabetes for 4 wk after
the injection of activated spleen cells. The number of rats treated is given in Table III.
Experiment 4 was designed to test if cells capable of the adoptive transfer of diabetes
were present in RT6-depleted nondiabetic DR-BB/W or LEW rats. Rats that had remained
nondiabetic after 1-4 wk of twice-weekly injections of anti-RT6.1 antibody were used as
spleen cell donors. Recipients were 30-d-old DP or DR-BB/W rats. A group ofnondiabetic,
RT6- DP-BB/W rats treated with anti-RT6.1 antibody or RPMI beginning at 30 d of age
were also used as spleen cell donors according to the same protocol . The number of rats
in each group is given in Table IV .
Results
Experiment 1: In Vivo Depletion of RT6' T Lymphocytes.
￿
Peripheral lymphoid
tissues of intact DR-BB/W rats contained normal numbers of RT6' T cells
(Table I). Doses of DS4.23 mAb ?0 .3 mg/kg body weight resulted in essentially
complete (>95%) depletion of RT6+ lymph node cells (Table I). The circulating
RT6+ T cell population remained depleted for at least 72 h after a single
injection of mAb (data not shown). The effectiveness of anti-RT6.1 treatment
was independent of age.
In vivo treatment of LEW (RT6') and DR-BB/W rats with anti-RT6.1 (0 .3
mg/kg) slightly decreased the relative proportions of the helper/inducer
(W3/25+) and suppressor/cytotoxic (OX8+) lymph node T cell subsets (Table 1).
Rat strain Treatment
RT6.1
Percentage
RT6.2
of positive
OX8
cells
W3/25 Ig
Anti-RT6.1 <1 .0 <1 .0 10.2 54.8 35 .8 DR-BB/W Medium 30.3 <1 .0 19.0 50.6 22.1
Anti-RT6.1 <1 .0 <1 .0 6.7 47.9 47.7 LEW Medium 42.9 <1 .0 19.4 55.2 26.2
Anti-RT6.1 <1 .0 56.0 24.4 50.9 22 .6 WF Medium <1 .0 57.6 29.4 50.3 21 .4TABLE II
Frequency ofDiabetes in Susceptible (DP) andResistant(DR) BB/W and Lewis
(LEW) Rats After Administration ofDS4.23Anti-RT6.1 Antibody
at DifferentAges
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Rats were injected twice weekly for 4 wk with 0.3 mg/kg DS4.23 anti-RT6.1 mAb
and tested for diabetes until 1 wk afterthe last injection. Data on the DP-BB/W rats
are through 60 d of age, when spontaneous diabetes typically begins to occur. The
DP-BB/W rats were tested for diabetes through 120 d of age. All diabetic rats had a
plasma glucose ?200 mg/dl. 4 of 12 (33%) RT6-depleted DP rats became diabetic as
compared with 2 of 6 (33%) controls. These rates are comparable to those observed
in thecolony as a wholeand suggest that diabetes in the DP ratis unaffected by anti-
RT6-treatment. A sample of 10 RT6-depleted DR rats from the group treated
beginningat 30 dofagewasstudied histologically at theend ofthe experiment. Four
(40%) were foundto have insulitis.
* p < 0.001 vs. control. No othercomparisons are statistically significant.
Injection ofWF (RT6b) rats with anti-RT6 .1 mAb had no effect on the level of
RT6+ peripheral Tcells. On the basis ofthesefindings, DS4.23 anti-RT6.1 mAb
was given twice weekly at a dose of 0.3 mg/kg to deplete RT6+ T cells in DR,
DP, and LEW rats in subsequent experiments.
Experiment 2.: Onset of Diabetes in RT6-depleted DR rats.
￿
When treated with
anti-RT6.1 mAb beginning at 30 d of age, 50% (19/38) of RT6-depleted DR-
BB/W rats, but none of 19 controls became diabetic (p < 0.001, Table 11). The
onset of diabetes was abrupt and the animals became ketotic. No rats became
diabetic during the first 14 d ofmAb treatment; 95% ofall cases occurred during
days 15-28 of mAb treatment. The mean age at onset ofdiabetes was 49 d. At
the end of the experiment, a sample of 10 nondiabetic RT6-depleted DR rats
was studied histologically; 4 of the 10 (40%) pancreata showed insulitis.
In contrast, diabetes could not be induced in DR-BB/W rats given anti-RT6.1
mAbbeginningwhenthey were 60dofagedespite comparable (>95%)depletion
ofRT6+ lymph node cells (Table II). There was no difference between DR rats
treated with mAb beginning at 60 d of age and untreated control DR rats with
respect to diabetes. The 2.8% occurrence rate in the RT6-depleted, 60-d-old
group corresponds closely with the rate of spontaneous diabetes in DR rats in
our colony as a whole (<3%). Table II also shows that depletion ofRT6+ T cells
in 30-d-old LEW rats did not induce diabetes.
Treatment of 30-d-old DP-BB/W rats with anti-RT6.1 mAb for 4 wk did not
affect the frequency of diabetes, a result that was expected since DP-BB/W rats
have no RT6+ peripheral Tcells (31). No diabetes occurred in either anti-RT6-
Strain Age
d
Treatment Number
studied
Frequency of
diabetes
n
DR-BB/W 30 Anti-RT6 38 19 50*
Control 19 0 0
DR-BB/W 60 Anti-RT6 43 1 2
Control 10 0 0
Anti-RT6 16 0 0 LEW 30 Control 6 0 0
DP-BB/W 30 Anti-RT6 12 0 0
Control 6 0 0466
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TABLE III
Induction ofDiabetes in RT6-depleted Resistant BB/W (DR-BB/W) and Lewis
(LEW) Rats After Injection of Con A-activated Spleen Cellsfrom Acutely
Diabetic BB/W Rats
All recipientrats were nondiabetic when tested. The anti-RT6-treated DR rats were
selected from among those that failed to develop diabetes after 3 wk of antibody
administration. All rats were given 40 X 106 Con A-activated spleen cells obtained
from acutely diabetic BB/W rats 1 wk afterthe last injection ofanti-RT6.1 antibody.
Rats were tested for diabetes twice weekly for 4 wk afterthe injection of the spleen
cells. All diabetic rats had a plasma glucose ?200 mg/dl. Overall X2 = 27 .86, p <
0.001 .
*p< 0.02 vs. control.
$p < 0.05 vs. group treated with anti-RT6.1 at 30 d. No other comparisons are
statistically significant.
treated or control DP rats before 60 d ofage. The frequencyofdiabetes between
60 and 120 d of age was also unaffected by anti-RT6 treatment, 4 of the 12
(33%) RT6-depleted rats and 2 of the 6 (33%) controls eventually becoming
diabetic.
Experiment 3: Induction of Diabetes in RT6-depleted DR-BB/W Rats.
￿
Con A-
activated spleen cells from acutely diabetic DP rats induced diabetes in 100%
(3/3) ofcontrol 30-d-old DP recipients, verifying that the cells used were capable
ofthe adoptive transfer ofdiabetes by established criteria (21). In the case of DP
recipients, onset of diabetes before they become 60 d old is interpreted as
evidence ofthe adoptive transfer ofdiabetes since <0.5% of animals in this age
group become spontaneously diabetic (21). DR-BB/W rats are resistant to the
adoptive transfer of diabetes unless immunosuppressed (23).
When Con A-activated spleen cells from acutely diabetic rats were given to
50-55-d-old RT6-depleted DR-BB/W recipients (treated with anti-RT6antibody
beginning at 30 d ofage), diabetes occurred in 5 of 7 (71%) as compared with 0
of 8 medium-treated controls (p < 0.01, Table 111). In contrast, when cells from
the same incubation were given to eleven 80-85-d-old RT6-depleted DR-BB/W
recipients (treated with anti-RT6 antibody beginning at 60 d of age), only one
(9%) became diabetic (p < 0.05 vs. group treated at 30 d of age, Table 3).
Similarly, injection of Con A spleen cells from acutely diabetic BB/W rats into
untreated DR or LEW rats or into RT6-depleted LEW rats failed to induce
diabetes (Table III).
Experiment 4: Adoptive Transfer ofDiabetes Using Spleen Cellsfrom RT6-depleted
DR-BB/WRats. In a preliminaryexperiment we comparedthe mitogen response
of spleen cells from RT6-depleted DR-BB/W rats with the response of medium
treated controls. After incubation in vitro with Con A (0.125-1 .0 tag/well), we
Recipient
strain Age
d
Treatment Number
studied
Frequency of
Diabetes
n %
Anti-RT6 7 5 71 DR-BB/W 30
Control 8 0 0
Anti-RT6 11 1 9$ DR-BB/W 60 Control 8 0 0
Anti-RT6 10 0 0 LEW 30 Control 6 0 0GREINER ET AL.
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TABLE I V
Frequency ofDiabetes in 30-d-old DP and DR BB/W Rats After the Injection of
Con A-activated Spleen Cells Obtainedfrom Nondiabetic Rats After Treatmentwith
Anti-RT6.1 Antibody
Donor spleen cells were obtained from nondiabetic RT6-depleted DR-BB/W or LEW rats, or
nondiabetic, anti-RT6.1-treated, RT6- DP-BB/W rats. Spleens were taken within 3 d after the
final injection of anti-RT6 antibody. Splenocytes were incubated in the presence of Con A (5
jug/ml) for 72 h before injection (21). Recipient rats were 30 doldat thetime of experimentation
and were tested fordiabetes for 4 wk afterthe injection of activated spleen cells. All diabetic rats
had a plasma glucose ?200 mg/dl.
* p <0.001 vs. control.
$p < 0.003 vs. control.
found no significant difference in [sH]thymidine incorporation between RT6-
depleted and control spleen cells (data not shown). We then tested spleen cells
obtained from intact and RT6-depleted rats and incubated with Con Afor their
ability to induce diabetes in both 30-d-old DP-BB/W and 30-d-old intact DR-
BB/W rats.
We first tested Con A-activated spleen cells from RT6 depleted DR rats that
had been treated with anti-RT6.1 mAb for 4 wk beginning at 30 d of age but
did not become diabetic. When these cells were injected into 30-d-old DP-BB/W
rats, 13 of 18 (72%) recipients become diabetic before 60 d ofage (p < 0.001
vs. cells from non-RT6-depleted controls). When they were injected into intact
DR-BB/W rats, 5 of 6 (83%) became diabetic within 3 wk (p < 0.005 vs. control
cells, Table IV).
Con A-activated spleen cells from DR rats treated for only 1 wk with anti-
RT6.1 antibody failed to induce diabetes in three DP recipients. Cells from rats
treated for 2 and 3 wk, respectively induced diabetes in 1 of 2 and 2 of2 ofDP
recipients before 60 d ofage.
These results contrast strongly with those obtained using spleen cells obtained
from nondiabetic, RT6-depleted DR rats that had been treated with anti-RT6.1
mAb for 4 wk beginning at 60 d ofage. Only 1 of 10 (10%) DP recipients and
0 of 5 DR recipients became diabetic (Table IV). The cells obtained from these
animals not only failed to transfer diabetes, but also failed to protect the DP
recipients from diabetes during the 60-120 d ofage high-risk period. By 120 d
of age, 9 of the 10 (90%) DP recipients of RT6-depleted, Con A-activated DR
spleen cells developed diabetes.
Spleen cell donors Type andnumber of spleen cell recipients
DP-BB/W DR-BB/W
Strain Age Treatment
Tested Diabetic Tested Diabetic
d n % n
Anti-RT6 18 13 72* 6 5 83$ DR-1313/W 30 Control 17 1 6 9 0 0
DR-BB/W 60 Anti-RT6 10 1 10 5 0 0
Control 8 0 0 5 0 0
Anti-RT6 8 0 0 ND ND LEW 30 Control 8 0 0 ND ND
DP-BB/W 30
Anti-RT6 12 0 0 ND ND
Control 6 0 0 ND ND468
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Con A-activated spleen cells from control (non-RT6-depleted) DR rats failed
to induce diabetes in either DP or DR recipients. Injection of activated spleen
cells from either RT6-depleted or control LEW rats into DP recipients neither
induced nor prevented diabetes (Table IV). Lastly, activated spleen cells from
nondiabetic anti-RT6-treated (0/12) or control (0/6) DP rats failed to transfer
diabetes to 30-d-old DP recipients.
Discussion
These data support the hypothesis that diabetes in the BB/W rat is influenced
by a regulatory T cell population that expresses the RT6.1 alloantigen. This
hypothesis derives from previous studies (29) showing that DP-BB/W rats, 40-
70% of which become spontaneously diabetic, lack RT6' T cells, while DR-
BB/W rats, <3% of which become diabetic, have these cells. The present study
now demonstrates that in vivo depletion of RT6' T cells is associated with the
appearance ofdiabetes in DR-BB/W rats.
Treatment with anti-RT6.1 mAb at either 30 or 60 d of age depleted RT6'
T cells in all DR rats tested. Depletion of RT6 T cells in 30-d-old DR rats was
associated with an increase in the frequency of diabetes from 0% in 19 controls
to 50% in 38 experimental animals. These was also an increase in insulitis, the
pathologic substrate of diabetes, in treated rats, and even nondiabetic RT6-
depleted DR rats were found to harbor spleen cells capable of the adoptive
transfer ofdiabetes. When treatmentofDR rats with anti-RT6 .1 mAb was begun
at 60 d of age, however, none ofthese effects could be observed.
Given these results, it is reasonable to speculate that during a critical devel-
opmental period a regulatory population of RT6' T cells may prevent sponta-
neous diabetes in DR rats. Once this temporal "window of susceptibility" has
passed, however, the importance ofthis regulatory Tcell population diminishes .
In this regard it is useful to note that RT6 T cells normally appear late in
ontogeny and do not reach adult levels until 40-50 days ofage (36; Mojcik, C.
J., D. L. Greiner, I. Goldschneider, and E. S. Medlock, manuscript in prepara-
tion). This corresponds closely to the age when RT6-deficient DP rats first show
evidence of insulitis and islet cell autoantibodies (1, 8), both of which are
indicators ofautoimmunity and harbingers of impending diabetes mellitus. It is
also of interest to note that an analogous temporal window has been observed
by Like et al. (43) who found that a brief (10 d) course of immunosuppression
with cyclosporine during the same age period conferred lasting protection from
diabetes.
Our data suggest that the RT6-depleted DR-BB rat may provide a useful
animal model of autoimmune diabetes that is complementary to the sponta-
neously diabetic DP-BB rat. In addition to diabetes itself, other similarities
between these models include a lack ofcirculating RT6' Tcells, the presence of
insulitis in both diabetic and a substantial percentage of nondiabetic animals,
abrupt onset ofhyperglycemia, a requirement for exogenous insulin for survival,
and the ability of spleen cells incubated in vitro with Con A to induce diabetes
in adoptive recipients.
It must, ofcourse, be cautionedthat in vivodepletion procedures such as those
used here can cause recipients to produce an immune response to injectedGREINER ET AL.
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antibody. This could manifest itself as anaphylaxis (44) or in the form of
antiidiotypic antibodies (45) that could negate the in vivo effect of the injected
mAb. In this study, however, we used an alloantibody (i.e., rat anti-rat), not a
xenotypic antibody, and it produced no detectable anaphylactic response. In
addition, we have observed that continuous in vivo administration of DS4.23
anti-RT6.1 mAb to RT6.1+ LEWratsfor up to 4 mo isaccompanied by persistent
depletion of RT6+ Tcells without evidence ofanaphylaxis (Greiner, D., and M.
Angelillo, unpublished observations).
The slight reduction in the levels ofcirculating T cellsafterdepletion ofRT6+
T cells in this rat model requires comment. It could be argued that the levels of
T cells were in fact significantly reduced, but were not accurately quantified by
our analyses. However, changes in lymphocyte subsets as small as 2-5% can be
accurately quantified by FACS analysis (40). Alternatively, it could be argued
that RT6+ Tcells are present but not detected by immunofluorescence analysis
due to antibody-induced modulation (46) of the RT6 antigen from the cell
surface. In related studies (Mojcik, C. J., D. L. Greiner, 1. Goldschneider, and
E. S. Medlock, manuscript in preparation), however, we have used thymecto-
mized rats to show that RT6' T cells do not reappear after in vivo depletion
with anti-RT6.1 mAb. This argues against a simple modulation mechanism to
account for our depletion results. Lastly, it might be argued that depletion of
RT6+ peripheral T cells could induce an efflux of T lymphocytes from the
thymus to peripheral lymphoid tissues. Thymocytes are RT6- (32), and require
between 10 and 14 d to express RT6 antigen on their surface after emigration
from the thymus (36). A rapid efflux of RT6- thymocytes could therefore
account for the relatively slight reduction in the levels ofperipheral W3/25+ and
OX8+ T cells observed in RT6-depleted rats, but further experiments would be
necessary to document this possibility conclusively.
The observation that spleen cells from RT6-depleted DR rats responded to
Con A as well as cells from intact DR rats was not surprising because we have
previously observed (Mojcik, C. J., et al., manuscript in preparation) that FACS
fractionated populations of RT6+ and RT6- LEW lymph node cells proliferate
similarly in the presence of this mitogen. Furthermore, both RT6+ and RT6- T
cells produce IL-2, a potent stimulator of T cell proliferation in vitro (47). In
contrast, DP rat lymphocytes proliferate poorly in response to Con A (48).
An important difference between RT6-depleted DR rats and DP rats is seen
in the ability of their spleen cells to transfer diabetes to adoptive recipients.
Previous studies (21-23), confirmed here, have shown that Con A-activated
spleen cells from acutely diabetic DP rats transfer diabetes to 30-d-old DP
recipients. Spleen cells from intact, nondiabetic DP or DR rats are incapable of
transfer according to this protocol (21, 23). In the present study, spleen cells
from nondiabetic RT6-depleted DR rats were found to be able to transfer
diabetes to 30-d-old DP adoptive recipients. Interestingly, these spleen cells were
also able to induce diabetes in untreated (nonimmunosuppressed) DR recipients.
Previous reports (23, 30) had indicated that Con A-activated spleen cells from
acutely diabetic rats could transfer diabetes only to DR rats that had first been
immunosuppressed.
A final important difference between RT6-depleted DR ratsand spontaneously470
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diabetic DP rats is the age at which diabetes typically appears. DR rats treated in
vivo with anti-RT6.1 mAb beginning at 30 d ofage became diabetic within 2-3
wk, on average when 49 d old. In contrast, the mean age at onset ofspontaneous
diabetes in DP rats is 89 d, with <0.5% ofdiabetes appearing before 60 d ofage
(1). Interestingly, in the small number of DR-BB/W rats (<3%) that do develop
spontaneous diabetes, the mean age at onset is ^-54 d.
There are at least three possible explanations for these observations. First, the
delayed onset of diabetes in DP rats could involve regulatory mechanisms that
depend on an RT6- cell population, for example the macrophage. DP-BB-
adherent cells, possibly macrophages, have been shown (48, 49) to have a potent
suppressive activity on T cell proliferation in vitro and may exert a regulatory
influence on effector T lymphocytes in vivo. Second, the difference in time of
onset of diabetes could be due to the selective expression of different effector
mechanisms. Recent studies (50, 51) suggest that NK cell activity is elevated in
DP rats and may be involved in the pathogenesis of diabetes. In contrast, NK
activity is normal to decreased in DR rats and RT6-depleted DR rats (52). A
third explanation for the delayed onset could be simply that fewer effector T
cells capable of inducing diabetes are available in DP rats because of their
lymphopenia (24-27). This concept of insufficient numbers of effector cells is
supported by the observation that diabetes in DP rats is accelerated by the
injection of Con A spleen cells from acutely diabetic rats (21-23) or RT6-
depleted DR rats (Table II), both ofwhich may be rich sources ofeffector cells.
Based on prior and present results, we propose that susceptibility ofDR-BB/W
rats to autoimmune diabetes depends on the delicate balance between its regu-
latory and effector cell populations (1). It has previously been observed that low-
dose irradiation (30) or cyclophosphamide (23), both of which primarily affect
suppressor Tlymphocytes (53), induces diabetes in DR rats. On the other hand,
a small percentage of DR rats spontaneously become diabetic (29), suggesting
that DR rats do have an effector cell population. Our interpretation of the
presence experiments is that in vivo depletion of RT6+ cells in DR rats disrupts
this delicate balance by removing the regulatory cell. According to our interpre-
tation, DR rats contain at least two cell populations that determine the clinical
expression ofdiabetes, a regulatory RT6' T cell subset that prevents it, and an
RT6- effector population that produces it.
In vivo depletion of RT6+ T cells in RTV LEW rats does not induce insulitis
or diabetes (Table II), suggesting that these normal animals lack the effector
cells present in DP and DR rats. However, one would expect RT6-depleted LEW
rats to become diabetic when injected with Con A-activated spleen cells from
acutely diabetic DP rats, but this was not observed (Table II). Assuming that the
injected DP spleen cells survived for a reasonable length of time in LEW
recipients (16), at least two explanations for the negative outcome suggest
themselves. First, Con A spleen cells from acutely diabetic rats may induce
diabetes by an indirect mechanism in DP and DR rats, perhaps by activating a
resident effector cell population. This explanation may not be tenable, however,
because Con A spleen cells induce diabetes in WF rats (23) that would also be
expected to lack effector cells. Alternatively, the effector mechanism importantGREINER ET AL.
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in diabetes may be restricted at the MHC (16, 18) and unable to induce diabetes
in histoincompatible LEW (RT1') recipients.
Since the RT6 antigen is known to occur only on a subset of peripheral T
lymphocytes (31, 32), it is likely that the regulatory RT6+ cell population
important in the prevention ofdiabetes in DR rats belongs to the Tcell lineage.
In other experiments, we have shown that injection oflymphocytes from DR or
WF rats to DP rats prevents diabetes (17, 18, 20). Cell fractionation has shown
that the protective cell belongs to the helper/inducer (W3/25) T cell subset (19),
and that the mechanism ofprotection is associated with the long-term persistence
ofdonor-origin lymphocytes, including RT6' Tcells (18). Taken together, these
results suggest that the important regulatory cell that protects DR rats from
diabetes belongs to the RT6 , W3/25' T cell subset.
Although the mechanism by which RT6' T cells prevent diabetes remains
uncertain, there is preliminary evidence that protection could be mediated by
soluble factors (lymphokines) produced by RT6' T cells. When DR or WF
lymphocytes sequestered in diffusion chambers are implanted into DP rats,
diabetes does not occur (54), suggesting that lymphokines could be a component
ofthe protective mechanism. IL-2, an important regulator ofcell activation and
proliferation (47), is known to be produced by RT6' T cells (Lubaroff, D. M.,
personal communication), and recent work by Prud'homme et al. (48) suggests
that deficient IL-2 production by helper/inducer T cells in DP rats might
contribute to their susceptibility to diabetes. We have recently observed (55),
however, that pharmacologic doses of human IL-2 given chronically to 30-d-old
DP rats do not alter either the frequency or time ofonset ofdiabetes. While IL-
2 may not be a protective lymphokine in the BB rat, it should be noted that the
RT6+ T cell population does not define a unique functionality and includes both
helper/inducer (W3/25') and suppressor/cytotoxic (OX8') populations (36).
Accordingly, many potential immunoregulatory lymphokines could be elabo-
rated by the RT6+ T cell population, and any one of these might be important
in determining susceptibility to diabetes.
Finally, it is interesting to note that anti-RT6.1 treatment of DP rats begun at
30 d of age did not affect the time or rate at which diabetes occurred in these
animals. This is consistent with ourprevious observation that DP-BB/W rats lack
RT6' T cells (31). In related studies (16, 56) we have determined that the
absence of RT6+ Tcells in DP rats can be traced to defects in the development
of their prothymocytes. The potential importance of prothymocyte defects in
BB rat diabetes is reinforced by the observation that transfer ofDP bone marrow
(an enriched source ofprothymocytes) into DR adoptive recipients renders these
irradiation chimeras susceptible to diabetes. Conversely, transfer of DR bone
marrow into DP recipients confers resistance to diabetes (16). This is immuno-
logically analogous to observations made in other animal models. Disease suscep-
tibility in the New Zealand mouse model of SLE (57) and in the motheaten
mouse model ofsevere combined immunodeficiency and autoimmunity (58) can
also be traced to defects in prothymocytes, and predisposition to experimental
allergic encephalomyelitis can be transferred from susceptible SJL/J mice to
histocompatible resistant B10.S mice by bone marrow cells (59). Taken together,
these results suggest that defects in the development of prothymocytes may be a472
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common predisposing factor for the T cell abnormalities important in the
pathogenesis of insulin-dependent diabetes mellitus and other genetically deter-
mined autoimmune disorders.
Summary
To investigate the role of RT6+ T cells in the pathogenesis of diabetes in
BB/W rats, we treated animals from the diabetes-resistant (DR) subline with anti-
RT6.1 lymphocytotoxic mAb. This depleted >95% of peripheral RT6+ T cells
but did not substantially reduce levels of circulating T cells or the in vitro
response of spleen cells to mitogen.
Treatment of 30-d-old DR BB/W rats in this way: (a) induced insulitis and
diabetes, (b) rendered nondiabetic RT6-depleted DR rats susceptible to the
adoptive transfer of diabetes by spleen cells from acutely diabetic BB/W rats,
and (c) yielded DR spleen cell populations capable of the adoptive transfer of
diabetes to diabetes-prone (DP) or DR recipients. Treatment of DR rats begin-
ning at 60 d of age failed to produce these effects.
These results suggest that both susceptibility and resistance to diabetes in the
BB/W rat are in part regulated by the RT6' T cell subset and provide evidence
for the importance of regulatory T lymphocytes in the pathogenesis of autoim-
munity and diabetes in BB/W rats.
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